Galux, a South Korean biotech pioneering AI-driven protein therapeutics discovery, has signed a research agreement with Boehringer Ingelheim to jointly explore the application of artificial intelligence (AI) in precision protein design for therapeutic development. The goal is to evaluate how AI can be leveraged to design purpose-specific protein molecules that meet precise scientific and translational needs, where conventional approaches face limitations. “Through this agreement, we aim to ex...